TherapeuticsMD, Inc. (NASDAQ:TXMD) is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.14 per share.
For the full year, analysts predict revenues of $ 60.63 million, while looking forward to loss of $ 0.63 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 15.10 million ~ $ 15.10 million
Full Year 2020 topline are forecasted in a range of$ 90.00 million ~ $ 110.00 million
Click Here For More Historical Outlooks Of TherapeuticsMD, Inc.
Previous Quarter Performance
TherapeuticsMD, Inc. unwinded loss for the second quarter of $ 0.19 per share, from the revenue of $ 10.70 million. The quarterly revenues escalated 75.99 percent compared with the same quarter last year. Wall street analysts are predicting, TXMD to report 2Q20 loss of $ 0.17 per share from revenue of $ 10.38 million. The bottom line results missed street analysts by $ 0.02 or 11.76 percent, at the same time, top line results outshined analysts by $ 0.32 million or 3.08 percent.
Stock Performance
On Friday, shares of TherapeuticsMD, Inc. has traded high as $ 1.30 and has cracked $ 1.21 on the downward trend, reaching $ 1.22 with volume of 3.88 million shares.
According to the previous trading day, closing price of $ 1.22, representing a 52.94 % increase from the 52 week low of $ 0.85 and a 56.08 % decrease over the 52 week high of $ 2.96.
The company has a market capital of $ 332.20 million and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Conference Call
TherapeuticsMD, Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.therapeuticsmd.com
TherapeuticsMD, Inc. operates as a womens health care product company in the United States. The companys hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil.
